Exploration if Saizen marketed solution for injection induces an immunogenic reaction

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-004263-47

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To determine whether the marketed Saizen solution for injection, administered according to the approved label for 9 months (39 weeks) in adults with GHD, induces the development of binding antibodies (BAbs).


Critère d'inclusion

  • Adult Growth Hormone Deficiency